2 FDA Decisions You Need to Watch Next Week
An experimental rare disease drug and another experimental drug that's been rejected three previous times are this week's must-watch FDA events.
Exelixis' Q4 Loss Widens as Investors Await Key Trial Data
Exelixis reports a wider fourth-quarter loss on higher R&D and SG&A expenses, but also points towards a number of key trial events in 2014.
Dow Debate: Can Merck & Co., Inc. Chase Johnson & Johnson In 2014?
After a strong start to the year, can Merck (NYSE: MRK) beat Johnson & Johnson (NYSE: JNJ) in 2014?